The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Introduction to checkpoint inhibitors and cancer immunotherapy
Open accessAbstract
This article introduces a series of reviews covering Checkpoint Inhibitors and Cancer Immunotherapy appearing in Volume 276 of Immunological Reviews. Immune responses are regulated by an exquisite system of checks and balances that enable effective protective immunity and tolerance. A number of immunological checkpoints control cells of the innate and adaptive immune system that determine their function. Stimulatory checkpoint pathways promote activation of naive T cells, as well as effector, memory and regulatory T cell responses. Inhibitory checkpoint pathways limit the threshold for T cell activation and duration of immune responses, and have diverse effects that regulate resolution of inflammation, tolerance and homeostasis. Tumors have hijacked inhibitory checkpoints to evade immune eradication. Blockade of the T cell checkpoint inhibitors CTLA-4 and PD-1 has shown remarkably durable clinical responses, but is effective in only a subset of patients.1-5 Combination therapy approaches are further improving response rates.6 These successes have stimulated great interest in determining the roles of innate and adaptive checkpoints in controlling the immunosuppressive tumor microenvironment, and developing strategies to target these checkpoints for cancer immunotherapy. Reviews in this issue of Immunological Reviews discuss innate and adaptive immunological checkpoints and their immunoregulatory roles in the pathogenesis of cancer, autoimmune diseases, and graft rejection. In this introduction, I will provide an overview of the checkpoint pathways in this issue. Insights into mechanisms regulating T cell activation led to the development of CTLA-4 and PD-1 blockade as strategies for cancer therapy. Our knowledge of T cell activation has progressed significantly from the two-signal concept for T cell activation, proposed by Lafferty and Cunningham to explain activation of naive T cells.7-9 According to this model, T cell activation requires a first signal provided by provided by interaction of antigenic peptide/MHC complex with the T cell receptor (TCR), which confers specificity to the response, and a second antigen-independent costimulatory signal. The interaction between the CD28 costimulatory receptor and its ligands CD80 (B7-1) and CD86 (B7-2) fulfilled many requirements for the costimulatory signal envisioned by Lafferty and Cunningham (see 10 this issue). However, the discovery of CTLA-4 as a CD28 homolog that possessed potent inhibitory functions, dramatically changed our perception of the two signal model.10-13 We now appreciate that there are a number of inhibitory (coinhibitory) as well as stimulatory (costimulatory) second signals that can modulate T cell receptor (TCR)—mediated T signals. Inhibitory checkpoints tune and shape activating signals to safeguard tolerance and immune homeostasis and protect against immune-mediated tissue damage. In addition, these inhibitory checkpoints are key mediators of T cell dysfunction (exhaustion) that develops during cancer and thereby prevents effective anti-tumor immunity. The critical role of these inhibitory checkpoints in cancer is illustrated by the remarkable effects of blockade of the CTLA-4 and PD-1 checkpoints for cancer.1, 5, 14 Seminal studies showing that anti-CTLA-4 blocking antibodies could promote anti-tumor immune responses in mouse tumor models15 led to the clinical development of the anti-CTLA-4 antibody ipilimumab for cancer therapy and its FDA approval for melanoma. The most striking effect of CTLA-4 blockade is the ability to induce long-lasting tumor regression.4 PD-1 pathway blockade has impressive clinical trial results with 30%-50% response rates in a broad range of tumors, and is FDA approved for melanoma, non-small cell lung cancer, kidney cancer, Hodgkin Disease, head and neck, and bladder cancer.2, 3, 5, 14, 16, 17 There is great interest in identifying approaches to extend this benefit to more patients. The success of anti-CTLA-4 and anti-PD-1 cancer immunotherapy has stimulated the search for other inhibitory checkpoints to target for cancer therapy. The innate and adaptive inhibitory checkpoint molecules reviewed in this issue (Figure 1) are therapeutic targets for cancer immunotherapy. T cell costimulatory and coinhibitory pathways provide critical checkpoints that regulate adaptive immunity. T cell costimulatory pathways fall into two major families, the Ig superfamily which includes CD28, ICOS,10 TMIGD2 (IGPR-1/CD28H)18 (which are CD28 family members) and CD226,19 and TNF:TNR receptor family, which includes Ox40 and 4-1BB.10 There is an abundance of inhibitory checkpoints which can influence T cell responses. These include the B7: CD28 family members CTLA-4, PD-1/PD-L, B7-H3 (CD276),18, 20 B7-H4 (B7x/B7S1/VTCN1),18, 20, 21 HHLA2 (B7H7/B7-H5)18 and VISTA (PD-1H, DD1alpha, c10orf54, Gi24, Dies1, SISP1),20, 22 the Ig superfamily members LAG-3,23 TIGIT and CD96,19 the ectonucleotidases CD39 and CD7324 and TIM-3 (T cell–immunoglo
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Nivolumab plus Ipilimumab in Advanced Melanoma
Wolchok, J. D., Kluger, H., Callahan, M. K., Postow, M. A., Rizvi, N. A., Lesokhin, A. M., Segal, N. H., Ariyan, C. E., Gordon, R.-A., Reed, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1302369 · Cited by 4,230
Tivol, E. A., Borriello, F., Schweitzer, A. N., Lynch, W. P., Bluestone, J. A., & Sharpe, A. H. (1995) · Immunity · doi:10.1016/1074-7613(95)90125-6 · Cited by 2,914
Self-citationLymphoproliferative Disorders with Early Lethality in Mice Deficient in Ctla-4
Waterhouse, P., Penninger, J. M., Timms, E., Wakeham, A., Shahinian, A., Lee, K. P., Thompson, C. B., Griesser, H., & Mak, T. W. (1995) · Science · doi:10.1126/science.270.5238.985 · Cited by 2,766
Schadendorf, D., Hodi, F. S., Robert, C., Weber, J. S., Margolin, K., Hamid, O., Patt, D., Chen, T.-T., Berman, D. M., & Wolchok, J. D. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2736 · Cited by 2,141
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Tim‐3 and its role in regulating anti‐tumor immunity
Das, M., Zhu, C., & Kuchroo, V. K. (2017) · Immunological Reviews · doi:10.1111/imr.12520 · Cited by 856
Cited by
SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
Veillette, A., & Chen, J. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.12.005 · Cited by 476
An early history of T cell-mediated cytotoxicity
Golstein, P., & Griffiths, G. M. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0009-3 · Cited by 284
Immune checkpoint inhibitor-induced colitis: A comprehensive review
Som, A., Mandaliya, R., Alsaadi, D., Farshidpour, M., Charabaty, A., Malhotra, N., & Mattar, M. C. (2019) · World Journal of Clinical Cases · doi:10.12998/wjcc.v7.i4.405 · Cited by 265
Suzman, D. L., Pelosof, L., Rosenberg, A., & Avigan, M. I. (2018) · Liver International · doi:10.1111/liv.13746 · Cited by 189
The SHH/GLI signaling pathway: a therapeutic target for medulloblastoma
Lospinoso Severini, L., Ghirga, F., Bufalieri, F., Quaglio, D., Infante, P., & Di Marcotullio, L. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1823967 · Cited by 61
Metadata
- Authors
- Sharpe, A. H.
- Venue
- Immunological Reviews
- Publisher
- Wiley
- Published
- 2017-03
- Volume
- 276
- Issue
- 1
- Pages
- 5-8
- ISSN
- 0105-2896 (ISSN-L)
- 1600-065X
- OpenAlex
- W2594491432
- Cited by
- 177
- References
- 8
- FWCI
- 2.39
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.